Skip to main content

Intranasal and inhaled fluticasone propionate for pollen-induced rhinitis and asthma

The full text article is not available.



Studies suggest that nasal treatment might influence lower airway symptoms and function in patients with comorbid rhinitis and asthma. We investigated the effect of intranasal, inhaled corticosteroid or the combination of both in patients with both pollen-induced rhinitis and asthma. Methods: 

A total of 262 patients were randomized to 6 weeks’ treatment with intranasal fluticasone propionate (INFP) 200 g o.d., inhaled fluticasone propionate (IHFP) 250 g b.i.d., their combination, or intranasal or inhaled placebo, in a multicentre, double-blind, parallel-group study. Treatment was started 2 weeks prior to the pollen season and patients recorded their nasal and bronchial symptoms twice daily. Before and after 4 and 6 weeks’ treatment, the patients were assessed for lung function, methacholine responsiveness, and induced sputum cell counts. Results: 

Intranasal fluticasone propionate significantly increased the percentages of patients reporting no nasal blockage, sneezing, or rhinorrhoea during the pollen season, compared with IHFP or intranasal or inhaled placebo. In contrast, only IHFP significantly improved morning peak-flow, forced expiratory volume in 1 second (FEV1) and methacholine PD20, and the seasonal increase in the sputum eosinophils and methacholine responsiveness. Conclusions: 

In patients with pollen-induced rhinitis and asthma, the combination of intranasal and IHFP is needed to control the seasonal increase in nasal and asthmatic symptoms.

Keywords: fluticasone propionate; lung function; nasal symptoms; pollen-induced rhinitis and asthma; sputum eosinophils

Document Type: Research Article


Affiliations: 1: Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, Denmark 2: Department of Clinical Pharmacology, Aarhus University, Aarhus, Denmark 3: Department of Respiratory Diseases, Ghent University Hospital, Ghent, Belgium 4: Servizio di Fisiopatologia Respiratoria, Sesto San Giovanni, Giovanni, Italy 5: Department of Otorhinolaryngology, University of Ghent, Ghent, Belgium 6: University Hospital ‘Dubrava’, Zagreb, Croatia 7: Respiratory Cell and Molecular Biology, Faculty of Medicine, Southampton General Hospital, Southampton, UK 8: GlaxoSmithKline R&D, Greenford, UK

Publication date: July 1, 2005


Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more